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1 Background
 Health promotion, including maintenance of bone 
health, is essential for the well-being cancer survivors, 
which are growing in number 1）. Aging, natural 
menopause, and cancer treatments such as surgical 
oophorectomy, gonadotropin-releasing hormone (GnRH) 
agonists, chemotherapy-induced ovarian failure, 
androgen deprivation therapy (ADT), and aromatase 
inhibitors (AIs) all cause bone loss, which potentially 
increases the risk of osteoporosis and subsequent bone 
fractures 1）. Although there are many recommendations 
for the improvement of bone health in cancer survivors, 
most of these guidelines address women with breast 
cancer receiving AIs or GnRH agonists and men with 
prostate cancer receiving ADT 2-4）. 
 Prostate cancer (43%) and breast cancer (41%) 
are the most common cancers among male and female 
cancer survivors, respectively 5）. Therefore, bone health 
of these cancer survivors is a matter of high concern. 
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ABSTRACT
	 Background: Malignant lymphoma patients have a high risk of bone mineral density (BMD) loss caused by 
corticosteroid-containing chemotherapy. Bisphosphonates have been used to prevent bone loss: however, little is 
known about effects of denosumab, a fully humanized monoclonal antibody inhibiting osteoclast-mediated bone 
resorption.
	 Methods: This clinical trial was conducted in newly diagnosed lymphoma patients undergoing corticosteroid-
containing chemotherapy. BMD was evaluated at baseline, and patients with a lumbar spine T-score of ≤ -1 were 
subcutaneously administered once with 60 mg of denosumab (“Denosumab” group). Patients with a T-score > -1 were 
allocated to the “No treatment” group. BMD was reevaluated at 24 weeks after enrollment. Bone turnover markers 
(BTMs) were collected at 0, 2, and 24 weeks. 
	 Results: Forty-three patients were enrolled (19 in the “Denosumab” group and 24 in the “No treatment” group). 
Patients in the “No treatment” group had decreased T-scores for the lumbar spine or femoral neck (P < 0.0001 or P = 
0.0029, respectively) at 24 weeks after enrollment, whereas both T-scores were stable in the “Denosumab” group. Of 
the 18 patients in the “Denosumab” group, 12 had a T-score change from baseline (ΔT-score) of ≥ 0, whereas the 
remaining six patients had a ΔT-score < 0. These six patients had severely low T-scores at enrollment. Osteoclastic 
BTMs were strongly suppressed during the 24 weeks in the “Denosumab” group. The probability of major 
osteoporotic fracture or hip fracture in the “No treatment” group increased during the 24 weeks (P = 0.0195 or P = 0.0289, 
respectively), whereas pretreatment with denosumab prevented increased risks of both types of fractures. 
	 Conclusions: Our data suggests that BMD screening at diagnosis of lymphoma should be considered so that the 
bone health of lymphoma survivors can be improved with denosumab.
(Accepted November 5, 2018)
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Meanwhile, non-Hodgkin's lymphoma (NHL) is the 
fifth (4%) and sixth (4%) most common among male 
and female cancer survivors, respectively, with 569,820 
NHL survivors living in the United States in 2014 5）. 
 We may need to pay more attention to the bone 
health of NHL patients, as compared to other cancer 
patients, because the standard chemotherapy regimens 
for NHL include the use of corticosteroids, which 
are known to increase the risk of osteoporosis and 
fractures 6）. High-dose corticosteroids and alkylating 
agents such as cyclophosphamide, which often cause 
gonadal dysfunction, are thought to be the major causes 
of osteoporosis in patients with malignant lymphoma 7）. 
In fact, a previous study demonstrated that the use 
of chemotherapy is associated with significantly 
increased risk of fracture and osteoporosis in elderly 
patients with NHL 6）. Similarly, another study showed 
that adult lymphoma patients receiving chemotherapy 
experienced osteoporotic fractures and significant 
bone mineral density (BMD) loss in the lumbar 
spine and proximal femur 8）. 
 Bisphosphonates, which are effective inhibitors 
of osteoclastic bone resorption, have been used to 
prevent osteoporosis caused by cancer treatment in 
lymphoma patients 9, 10）. The second-generation 
bisphosphonate, pamidronate, reduces trabecular 
bone loss and thereby the risk of new vertebral fractures 
in patients with malignant lymphomas receiving 
chemotherapy 9）. Treatment with zoledronic acid, a third-
generation bisphosphonate, effectively stabilizes BMD 
and prevents bone loss in patients newly diagnosed 
with lymphoma receiving chemotherapy 10）. 
 A novel approach to fracture prevention is the 
use of denosumab 11）. It is a fully humanized monoclonal 
antibody against the receptor activator of nuclear 
factor-κB ligand (RANKL), a cytokine essential for 
the formation, function, and survival of osteoclasts 12）. 
By binding RANKL, denosumab prevents interaction 
with its receptor, RANK, on the surface of osteoclasts 
and osteoclast precursors and reversibly inhibits 
osteoclast-mediated bone resorption 13）. Denosumab, 
administered subcutaneously at a dose of 60 mg every 
six months, has been shown to increase BMD of the 
lumbar spine and total hip and reduce the incidence 
of new vertebral, nonvertebral, and hip fractures in 
postmenopausal women with osteoporosis 11）. 
 Denosumab has been associated with increased 
BMD at all sites and a reduction in the incidence of new 
vertebral fractures among men receiving ADT for 
nonmetastatic prostate cancer 14）. Adjuvant denosumab, 
administered at 60 mg doses twice a year, reduced the 
risk of clinical fractures in postmenopausal women 
with breast cancer receiving AIs 15）. Extending the 
application of denosumab to lymphoma patients was 
suggested 16）; however, little is known about the effects 
of denosumab on bone loss caused by cancer treatment 
in lymphoma patients. 
 Therefore, we investigated the effect of denosumab 
on the prevention of bone loss in newly diagnosed 
malignant lymphoma patients undergoing corticosteroid-
containing chemotherapy in this study. Random 
allocation was not performed because it was considered 
unethical. In a previous report 17）, denosumab improved 
BMD in women with osteoporosis with long-term 
glucocorticoid treatment of autoimmune or inflammatory 
conditions. Further, it has been demonstrated that 
denosumab is effective for fracture prevention in 
patients with prostate 14） or breast 15） cancer.
2 Methods
2・1 Study design and objective
 The aim of this single-center, open-label, non-
randomized, controlled clinical trial is to evaluate 
the efficacy and safety of denosumab for prevention of 
bone loss in newly diagnosed malignant lymphoma patients 
undergoing corticosteroid-containing chemotherapy. 
The primary endpoint was a change in BMD and bone 
turnover markers (BTMs). Secondary endpoints 
included the incidence rate of vertebral fractures 
and adverse events (AEs). 
2・2 Patients
 Eligible patients were age between 20 and 90 
years with newly diagnosed malignant lymphoma 
and were to undergo chemotherapy containing 
corticosteroids. Other eligibility criteria included 
Eastern Cooperative Oncology Group (ECOG) 
performance status (PS) 0-2, and an expected survival of 
more than three months. Adequate pulmonary, cardiac, 
renal, and hepatic function was required. Exclusion 
criteria included previous use of bisphosphonate; 
active concomitant malignancy; severe psychiatric 
disorders; women who are pregnant or in lactation; 
hypersensitivity to denosumab; currently active dental 
problems; and unexplained hypocalcemia. 
2・3 Treatment
 Newly diagnosed malignant lymphoma patients 
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were divided into two groups based on the level of 
their T-scores, which was the BMD measured by 
dual-energy X-ray absorptiometry (DXA). Patients with a 
T-score of ≤ -1.0 for the lumbar spine were subcutaneously 
administered a single 60 mg dose of denosumab one 
day before the start of corticosteroid-containing 
chemotherapy. All patients who received denosumab 
were also administered an oral nutritional supplement 
containing at least 600 mg calcium and 400 IU vitamin 
D (denotas®), daily, throughout the study period. 
Patients with a T-score of > -1.0 for the lumbar spine 
underwent corticosteroid-containing chemotherapy 
without denosumab. 
2・4 Bone mineral density and bone turnover markers
 We measured BMD of the lumbar spine (L2 to 
L4) and the femoral neck using DXA (Hologic QDR-
4500A; Bedford, MA) at baseline and 24 weeks after 
the administration of denosumab. Concentrations of the 
following BTMs were measured from fasting serum 
samples collected in the morning at baseline, 2, and 
24 weeks after the administration of denosumab: 
tartrate-resistant acid phosphatase 5b (TRACP-5b), 
serum type I collagen cross-linked N-telopeptide (sNTx), 
intact procollagen type I N-terminal propeptide (I-PINP), 
osteocalcin (OC), and bone alkaline phosphatase (BAP). 
BTMs were evaluated by the central laboratory, 
SRL (Tokyo, Japan). TRACP-5b was analyzed by 
the enzyme immunoassay (EIA), sNTx by the enzyme-
linked immunosorbent assay (ELISA), I-PINP and OC 
by the radioimmunoassay (RIA), and BAP by the 
chemiluminescent enzyme immunoassay (CLEIA). 
2・5 Fracture Assessment
 Lateral thoracic and lumbar spine radiographs 
were obtained at baseline and 24 weeks after the 
administration of denosumab. Prevalent vertebral 
fractures were diagnosed using standard criteria 18）. 
The fracture risk was assessed using the online 
WHO Fracture Risk Assessment Tool, FRAX® at 
http://www.shef.ac.uk/FRAX/tool.jsp, as described 
previously 18）. In brief, completion of the following 12 
fields was required: age (years); sex (male or female); 
height (cm); weight (kg); history of previous fracture; 
history of parental hip fracture; current smoking; 
oral glucocorticoids exposure (more than three months 
at a dose of 5 mg of prednisolone daily or more); diagnosis 
of rheumatoid arthritis; secondary osteoporosis; 
daily alcohol intake of more than three units; and 
femoral neck DXA score (g/cm 2 ). 
2・6 Adverse events
 All patients were questioned concerning AEs at 
each visit. All AEs were assessed, regardless of 
determination of causality by the investigators. 
Safety laboratory tests including serum chemistry and 
hematology were assessed three times a week for 
three weeks after the administration of denosumab. 
An AE was considered “serious” if it resulted in any 
of the following outcomes: death, a life-threatening 
AE, inpatient hospitalization or prolongation of 
existing hospitalization, a persistent or significant 
incapacity or a substantial disruption in the ability to 
conduct normal life functions, or a congenital anomaly 
or birth defect 17）. We prespecified AEs of interests, 
such as hypocalcemia, bacterial cellulitis, infection, 
eczema, events potentially related to hypersensitivity, 
cardiovascular disorder, malignant or unspecified 
tumors, fracture healing complication, atypical 
fracture of femur, and osteonecrosis of the jaw, as 
previously described 19）. This was based on the Food and 
Drug Administration (FDA) safety analysis, announced 
at a meeting of the Advisory Committee for Reproductive 
Health Drugs on August 13, 2009 17）, which identified 
the following as “AEs of special interest” for denosumab: 
infection, new malignancy, tumor progression, 
dermatologic events, hypocalcemia, osteonecrosis of the 
jaw, bone histomorphometry findings, hypersensitivity/
immunogenicity, cardiovascular adverse events, 
pancreatitis, and ocular adverse events. 
2・7 Statistical methods
 All statistical analyses were performed using 
GraphPad Prism version 5.0 (GraphPad Software, 
La Jolla, CA). All values are presented as mean ± 
standard error of the mean (SEM). Statistical 
significance was determined using the Student's t-test 
in the case of normally distributed data, otherwise the 
Mann-Whitney U test was performed. For comparisons 
of data from the same patient, the paired Student's 
t-test was used. The Fisher exact test was used to evaluate 
the association between two categorical variables. The 
Spearman correlation coefficient was used to estimate 
the correlation between two continuous variables. All 
tests were two-sided. P values < 0.05 were considered 
statistically significant. 
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3 Results
3・1 Patient enrollment
 Fifty-five patients with newly diagnosed malignant 
lymphomas seen at our department from October 2013 
until September 2015 were screened for eligibility to 
enter this trial (Fig. 1 ). Twelve patients were excluded 
for the following reasons: no chemotherapy undertaken 
(N = 3); chemotherapy without corticosteroids undertaken 
(N = 4); currently active dental problems (N = 2); 
refusal to participate (N = 1); and previous use of 
bisphosphonate (N = 2). Finally, 43 patients consented 
for this study. Nineteen patients with T-scores of ≤ -1.0 
for the lumbar spine were treated with denosumab 
before chemotherapy containing corticosteroids 
( “Denosumab” group). Meanwhile, 24 patients with 
T-scores of > -1 for the lumbar spine underwent 
corticosteroid-containing chemotherapy without 
pretreatment with denosumab ( “No treatment” group). 
The data cut-off date for this analysis was March 27, 
2016. Eighteen patients in the “Denosumab” group and 
18 patients in the “No treatment” group completed the 
protocol. 
 Patient demographics and baseline characteristics 
are described in Table 1. Both, T-scores and BMDs, 
for lumbar spines and femoral necks of patients in 
the “No treatment” group were higher than thoses 
of “Denosumab” patients because patients with 
lumbar spine T-scores of > -1.0 were allocated to the “No 
treatment” group. The male/female ratio in the “No 
treatment” group was higher than that in the 
“Denosumab” group. The “No treatment” and 
“Denosumab” groups had similar demographics in terms 
of age, type of lymphoma, and chemotherapy regimen. 
 We examined the following five BTMs at baseline 
(Table 1 ): TRACP-5b, sNTx, I-PINP, OC, and BAP. 
TRACP-5b and sNTx are BTMs for osteoclastic bone 
resorption 20）. The former is a surrogate marker of 
osteoclast number and the latter is that of osteoclast 
function. I-PINP, OC, and BAP are BTMs of osteoblastic 
bone formation 21）. Although there were no differences 
between the two groups in the serum levels of 
TRACP-5b, sNTx, I-PINP, and BAP, OC of patients 
Figure 1. Enrollment, allocation, and follow-up of the study patients.
Table 1. Characteristics of patients
No treatment
(n=24）
Denosumab
(n=19） P value
T-score, mean（±SD）
　　Lumbar spine（L1-L4）
　　Femoral neck
0.6（±1.4）
-0.3（±0.8）
-1.9（±0.7）
-1.5（±0.9）
<0.0001
<0.0001
BMD（g/cm2）, mean（±SD）
　　Lumbar spine（L1-L4）
　　Femoral neck
1.12（±0.19）
0.90（±0.12）
0.80（±0.08）
0.71（±0.10）
<0.0001
<0.0001
Age, median（range） 66（20-86） 66（54-81） 0.1459
Male sex, n（%） 16（66.7） 3（15.8） 0.0016
Type of lymphoma, n（%）
　　DLBCL
　　Others
16（66.7）
8（33.3）
14（73.7）
5（26.3）
0.7433
Chemotherapy, n（%）
　　R-CHOP-like regimen
　　Others
22（91.7）
2（8.3）
17（89.5）
2（10.5）
1.0000
BTM, mean（±SD）
　　TRACP-5b（mU/dL）
　　sNTx（nmol BCE/L）
　　I-PINP（µg/L）
　　OC（ng/mL）
　　BAP（µg/L）
516（±304）
20.1（±6.7）
36.1（±14.3）
5.0（±2.4）
13.8（±3.7）
526（±266）
24.0（±9.9）
43.6（±16.9）
7.2（±2.0）
13.2（±3.4）
0.9032
0.1312
0.1348
0.0034
0.5586
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in the “No treatment” group was significantly lower 
than that of patients in the “Denosumab” group (P 
= 0.0034). Furthermore, the serum level of OC in all 
patients was negatively correlated with T-scores for the 
lumbar spine (P = 0.0090). 
3・2 Bone mineral density
 As shown in Fig. 2, T-scores of lumbar spines or 
femoral necks of patients in the “No treatment” 
group decreased during the 24 weeks of corticosteroid- 
containing chemotherapy (P < 0.0001 or P = 0.0029, 
respectively). Pretreatment with denosumab, yielded 
sustained T- scores throughout the 24 weeks. Upon 
the assessment of BMDs (Fig. 3 ), almost the same data 
as that displayed in Fig. 2 was obtained: BMD decreased 
during corticosteroid-containing chemotherapy, however, 
the pretreatment of denosumab sustained BMD. 
 Further analysis revealed that the lumbar spine 
Figure 2. T-score at baseline and 24 weeks after enrollment. T-score at baseline (0 W) and 24 weeks after enrollment (24 W) 
of lumbar spine and femoral neck in the “No treatment” or “Denosumab” groups are shown.
Figure 3. BMD at baseline and 24 weeks after enrollment. BMD at baseline (0 W) and 24 weeks after enrollment (24 W) of 
lumbar spine and femoral neck in the “No treatment” and “Denosumab” groups are shown. 
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and femoral neck T-score changes from the baseline 
(ΔT-score) for patients in the “Denosumab” group 
was higher than that for “No treatment” patients (P 
< 0.0001 or P = 0.0015, respectively) (Fig. 4 ). Upon 
assessment of the percentage BMD change from 
baseline (ΔBMD), patients in the “Denosumab” group 
had higher ΔBMD than those in the “No treatment” 
group for the lumbar spine (P < 0.0001) and the 
femoral neck (P = 0.0023). 
 Of the 18 patients treated with denosumab, 12 
had ΔT-scores ≥ 0, whereas the remaining six had 
ΔT-scores < 0 for the lumbar spine (Fig. 4a ). Then, 
we analyzed the possible factors affecting T-score 
changes (Table 2 ). Comparing the two groups, 12 
patients with a ΔT-score ≥ 0 had higher lumbar spine 
T-scores or BMDs before the start of chemotherapy 
than that of the six patients with a ΔT-score < 0 (P = 
0.0214 or P = 0.0168, respectively). Therefore, denosumab 
could not easily increase the T-scores of patients with 
severely lowered T-scores or BMDs before chemotherapy. 
 Next, we analyzed whether corticosteroids dose-
dependently decreased bone mineral. There was no 
correlation between the cumulative dose of 
corticosteroids and the ΔT-score or ΔBMD in the 
Figure 4. T-score change and BMD percent change from baseline. T-score change and BMD percent change from baseline in 
the “No treatment” and “Denosumab” groups of lumbar spine and femoral neck are shown.
Table 2. Factors affecting T-score change of lumbar spine in patients treated with 
denosumab
ΔT-score≥0
（n=12）
ΔT-score<0
（n=6） P value
T-score, mean（±SD）
　　Lumbar spine（L1-L4）
　　Femoral neck
-1.7（±0.4）
-1.0（±0.9）
-2.5（±1.0）
-2.1（±0.7）
0.0214
0.0569
BMD（g/cm2）, mean（±SD）
　　Lumbar spine（L1-L4）
　　Femoral neck
0.83（±0.04）
0.76（±0.11）
0.72（±0.11）
0.65（±0.07）
0.0168
0.0693
Age, median（range） 67（54-81） 68（56-75） 0.7944
BTM, mean（±SD）
　　TRACP-5b（mU/dL）
　　sNTx（nmol BCE/L）
　　I-PINP（µg/L）
　　OC（ng/mL）
　BAP（µg/L）
446（±312）
23.2（±10.0）
37.6（±15.6）
7.4（±2.1）
12.4（±3.6）
454（±201）
19.8（±11.6）
45.0（±18.2）
8.1（±2.2）
13.0（±3.4）
0.9038
0.9800
0.2940
0.8492
0.7674
Cumulative dose of PSL（mg） 1750（±1100） 1500（±1084） 0.6595
Cumulative dose of G-CSF（µg） 7725（±5525） 8250（±3706） 0.5776
41Denosumab prevents bone loss in newly diagnosed malignant lymphoma
“No treatment” group (P = 0.2596 or P = 0.2209, 
respect ively).  T hese results  i nd ic at e  th at 
corticosteroids could decrease bone mineral, even if 
the cumulative corticosteroid dose was not very high. 
We further analyzed granulocyte-colony stimulating 
factor (G-CSF), which was administered for the 
prevention of febrile neutropenia, since Asada N et 
al. demonstrated in a previous paper that G-CSF 
suppressed osteoblasts 22）. However, there was no 
relationship between the cumulative dose of G-CSF and 
the ΔT-score or ΔBMD for the lumbar spine in the 
“No treatment” group (P = 0.4052 or P = 0.4895, 
respectively).
3・3 Bone turnover marker
 Two BTMs of osteoclasts, TRACP-5b and sNTx, were 
clearly suppressed two weeks after the administration 
of denosumab (P < 0.0001 and P < 0.0001, respectively) 
(Fig. 5 ). This suppression was sustained until 24 
weeks after denosumab administration (P < 0.0001 and 
P < 0.0001, respectively). In contrast, TRACP-5b and 
sNTx did not fluctuate in patients not pretreated with 
denosumab. 
 Next, three BTMs of osteoblasts, I-PINP, OC, and 
BAP, were analyzed (Fig. 6 ). I-PINP was suppressed 
after two weeks in both the “No treatment” and 
“Denosumab” groups, perhaps because of the 
administration of corticosteroids (P = 0.0036 or P < 0.0001, 
respectively). After 24 weeks, I-PINP was elevated 
reactively in the “No treatment” group (P = 0.0005); 
however, it was still suppressed in the “Denosumab” 
group (P = 0.0014). Assessment of other BTMs for 
osteoblasts revealed that OC and BAP exhibited the 
same trend. 
3・4 Vertebral fracture
 New vertebral fractures were identified by 
comparing standard x-rays from week 0 with that 
from week 24. Of the 18 patients (16.7%) in the “No 
treatment” group, three had new fractures, whereas 
no patients had new fractures in the “Denosumab” 
group. However, the differences between the two groups 
were not statistically significant (P = 0.2286), 
possibly because of small sample size. Further, we 
assessed the 10-year probability of fracture using 
FRAX algorithms (Fig. 7 ). The probability of major 
osteoporotic (OP) fracture (of clinical spine, forearm, 
hip, or shoulder), or hip fracture of patients from the 
“No treatment” group, increased during the 24 weeks 
(P = 0.0195 or P = 0.0289, respectively), whereas 
pretreatment with denosumab prevented the increase 
in risk of both fractures in patients. 
3・5 Adverse events (AEs)
 AEs of interest are shown in Table 3. In the “No 
treatment” group, there was one patient with eczema. 
Figure 5. BTMs of osteoclastic bone resorption. TRACP-5b and sNTx at baseline (0 W), 2 weeks or 24 weeks after enrollment 
(2 W or 24 W) in the “No treatment” and “Denosumab” groups are shown.
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Figure 6. BTMs of osteoblastic bone formation. I-PINP, OC and BAP at baseline (0 W), 2 weeks or 24 weeks after enrollment (2 W 
or 24 W) in the “No treatment” and “Denosumab” groups are shown.
Figure 7. Probability of major OP fracture and hip fracture. Probability of major OP fracture and hip fracture at baseline (0 W) 
and 24 weeks after enrollment (24 W) in the “No treatment” and “Denosumab” groups are shown.
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In the “Denosumab” group, there were two patients 
with hypocalcemia and one with cardiovascular disorder 
(hypertension). These AEs were not considered 
“serious”. Osteonecrosis of the jaw was not observed 
in patients from either group. Two patients experienced 
hypocalcemia with calcium levels of > 7 and < 8 mg/dL 
on days 4 and 9, respectively. They had lower calcium 
levels on day 0 compared with that of other patients. 
Spontaneous recovery from hypocalcemia was 
achieved without any additional treatment.
4 Discussion
 After the screening for eligibility to enter this 
trial, patients were allocated to one of two groups 
based on their lumbar spine T-scores. This study 
was designed as a non-randomized trial because it 
would be unethical to allocate patients with osteoporosis 
to the “No treatment” group. Especially because it 
has been previously demonstrated that denosumab 
is effective for fracture prevention in patients with 
prostate 14） or breast 15） cancer.
 Patients with low BMD were allocated to the 
“Denosumab” group, making the “Denosumab” group 
female-dominated. In this group, OC, one of the 
osteoblastic bone formation markers, was higher 
than that in the “No treatment” group at the time 
of enrollment (Table 1 ). A possible explanation for 
this observation is that free osteocalcin is available 
in the blood when the bone mineralization rate is 
low since osteocalcin influences bone mineralization, 
in part, through its ability to bind with high affinity to 
the mineral component of bones, hydroxyapatite 23, 24）. 
This might also explain the increased serum osteocalcin 
concentration in the serum of osteoporotic postmenopausal 
women 23）. Another important finding of our examination 
regarding OS was that the serum level of OC in all 
patients was negatively correlated with the lumbar 
spine T-scores. This result suggests that the serum 
OC level can be used as a surrogate marker, 
substituting for the lumbar spine T-scores, which has to 
be measured by DXA examination consuming time 
and money.  
 Most patients pretreated with denosumab had 
increased lumbar spine T-scores after chemotherapy; 
however, some patients had decreased T-scores in 
spite of denosumab treatment. Then, we examined the 
factors affecting the lumbar spine T-score changes 
in patients treated with denosumab (Table 2 ). The 
result was that the patients with decreased T-scores 
after chemotherapy had severely low lumbar spine 
T-scores or BMDs at enrollment, unlike patients 
with increased T-scores after chemotherapy. Based 
on this finding, patients with severely low T-scores 
at enrollment might have to be treated with not only 
denosumab, but also some concomitant medication before 
chemotherapy. A candidate drug to co-administrate with 
denosumab may be teriparatide, a recombinant human 
parathyroid hormone 1, 24）. It has been demonstrated 
that two years of combined teriparatide and denosumab 
treatment improves bone microarchitecture and has 
a higher estimated strength than the individual 
administration for postmenopausal osteoporosis, 
particularly in the cortical bone 25, 26）. 
 In this study, 24 weeks after the administration 
of denosumab, I-PINP, an osteoblastic BTM, was 
elevated reactively after the transient suppression 
at 2 weeks in the “No treatment” group; however, it was 
still suppressed in the “Denosumab” group (Fig. 6 ). 
These results indicate that decreased BMD in the 
“No treatment” group may recover spontaneously and 
increased BMD in the “Denosumab” group may gradually 
reduce. To address this concern, an informative 
Table 3. Adverse events of interest
No treatment
(n=24)
Denosumab
(n=19)
Osteonecrosis of the jaw 0 0
Hypocalcemia 0 2
Hypersensitivity 0 0
Atypical femoral fracture 0 0
Bacterial cellulitis 0 0
Eczema 1 0
cardiovascular disorder 0 1
infection 0 0
malignant or unspecified tumors 0 0
fracture healing complication 0 0
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report studied postmenopausal women receiving a 
placebo or 60 mg of denosumab every six months for 
24 months, followed by 24 months without treatment. 
After discontinuation, BMD declined, but the patients 
previously treated with denosumab maintained higher 
BMDs than patients previously treated with the placebo 27）. 
 Although the only one denosumab dose was 
administered to patients in this study, it was enough to 
prevent a decrease in T-scores and BMDs, unlike 
patients without denosumab treatment (Fig. 2 and 3 ). 
Nevertheless, whether continuous administration of 
denosumab after chemotherapy is necessary is 
unclear. Appropriate number of times that denosumab 
should be administered is still under evaluation; however, 
we recommend continuous dosing, if the patients are 
postmenopausal women, provided circumstances permit 
it. This recommendation is based on a case of multiple 
vertebral fractures soon after discontinuation of six 
doses of denosumab in a breast cancer patient 
treated with AIs 28）. 
 Further, application of denosumab to patients 
with a lumbar spine T-score of > -1, allocated to the 
“No treatment” group in this study, should be examined. 
We believe that denosumab protects any patients with 
lymphoma undergoing corticosteroid-containing 
chemotherapy from bone loss; however, a large-scale 
clinical trial may be necessary to prove statistical 
significance in the incidence of vertebral fracture. 
5 Conclusions
 We demonstrated that denosumab prior to 
corticosteroid-containing chemotherapy protects NHL 
patients with a T-score < -1 from decrease in T-score 
or BMD. Our findings suggest that evaluating BMD 
at diagnosis of NHL should be considered. This would 
enable better bone health in an increasing number 
of lymphoma survivors by simply administering 
denosumab. 
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副腎皮質ステロイドを用いる化学療法に伴う悪性リンパ腫患者の
骨喪失をデノスマブで予防する前向き非無作為化臨床試験
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吉 田 正 宏1），井 畑 壮 詞1），橋 本 亜 香 利1），神 原 悠 輔1），堀 口 拓 人1），
宮 西 浩 嗣1），小 船 雅 義2），加 藤 淳 二1）
1） 札幌医科大学腫瘍内科学講座
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　悪性リンパ腫患者は，副腎皮質ステロイドを用いる化
学療法のため，骨密度減少のリスクが高い．ビスホスホ
ネートは骨量減少の予防に用いられてきたが，一方で破
骨細胞に対する完全人化モノクローナル抗体であるデノ
スマブの効果は明らかではない．
　今回我々は，デノスマブが副腎皮質ステロイドを用い
る化学療法を行う悪性リンパ腫患者の骨密度低下を予防
するか検討した．主要評価項目は，骨密度と骨代謝マー
カーの変化，副次評価項目は椎体骨折と有害事象とした．
腰椎 T スコア≦ -1 の骨塩減少群をデノスマブ投与群，
腰椎 T スコア＞ -1 の骨塩正常群は非投与群とした．デ
ノスマブ群は，化学療法開始時にデノスマブ 60mg を皮
下投与された．43 人が登録された（デノスマブ 19 人，
無治療 24 人）．
　骨密度は，非投与群では有意に低下したが（P<0.0001），
デノスマブ群では骨密度は保たれた．また破骨細胞の骨
吸収マーカーは，非投与群では変化しなかったものの，
デノスマブ群においては有意に低下した（P<0.0001）．
　非投与群における，骨粗鬆症関連骨折または大腿骨頸
部骨折の確率は 24 週間で有意に増加した（P=0.0195, 
P=0.0289），一方でデノスマブ群では骨折のリスク増加
は認めなかった．
　以上より，悪性リンパ腫患者の T スコア≦ -1 骨塩減
少群において，デノスマブは骨密度低下を予防すること
が示された．悪性リンパ腫診断時に，骨密度のスクリー
ニングは全例で検討されるべきである．
